an open-label, single-arm, non-comparative study to evaluate the efficacy, tolerability and convenience of Invanz [ertapenem sodium] in the treatment of community-acquired sepsis in adults
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2014
At a glance
- Drugs Ertapenem (Primary)
- Indications Bacterial infections; Sepsis
- Focus Therapeutic Use
- Sponsors Merck & Co
- 01 Feb 2007 Status changed from recruiting.
- 25 Nov 2006 New trial record.